Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 832 · Ensuring Pathways to Innovative Cures Act of 2025 ·

EPIC Act of 2025

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 1320f–1 Selection of negotiation-eligible drugs as selected drugs

+2 −01 of 2 shown
More for 42 U.S.C. § 1320f–1
Read § 1320f–1Only this section
2 changes the bill asks for here, 1 carried out
  1. Not carried out:

    by striking year, at least 7 and inserting “year—(I) for initial price applicability years 2026 and 2027, at least 7; and

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: striking QTEXT and inserting “ year — QCONTENT; and
  2. Carried out:

    by adding at the end the following:(II) for initial price applicability year 2028 and each subsequent initial price applicability year, at least 11 years will have elapsed since the date of such approval; and.

§ 1320f–1(e)(1)In general(A)–(B)

Start of § 1320f–1 to (e)(1)(A) unchanged ·

(i) that is approved under section 355(c) of title 21 and is marketed pursuant to such approval;

(ii) for which, as of the selected drug publication date with respect to such initial price applicability year, at least 7 years will have elapsed since the date of such approval; and

(II) [inserted: for initial price applicability year 2028 and each subsequent initial price applicability year, at least 11 years will have elapsed since the date of such approval; and]

(iii) that is not the listed drug for any drug that is approved and marketed under section 355(j) of such title.

(B) Biological products A biological product—

Rest of § 1320f–1 unchanged ·

Step through the changes